Unknown

Dataset Information

Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.


ABSTRACT:

Background

The risk of symptomatic intracranial haemorrhage (sICH) after thrombolysis is low but severe. Lower dose of alteplase may reduce the risk of sICH. We aim to identify subsets of patients who could benefit from lower dose of alteplase compared with standard dose.

Methods

Data from two observational registries were pooled together. A total of 3479 patients who had acute ischaemic stroke were entered into the interaction tree model. The response variable was the rate of sICH per the definition of the National Institute of Neurological Disorders and Stroke Study. Clinical improvement was measured by the National Institutes of Health Stroke Scale (NIHSS) and defined as NIHSS 0 or 1 or an improvement of more than 4 points (within 7 days or at discharge). Rare event logist

SUBMITTER: Dong Y 

PROVIDER: S-EPMC7804063 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature